{"id":"standard-dose-ptcy","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Bleeding"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"null","effect":"Cerebrovascular accident"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PTCY works by selectively inhibiting the P2Y12 receptor, which is involved in platelet activation and aggregation. This leads to a reduction in platelet aggregation and subsequent thrombus formation.","oneSentence":"PTCY is a small molecule that targets the P2Y12 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:07.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":"Allogeneic Stem Cell Transplant Recipient","enrollment":209},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06705062","phase":"PHASE3","title":"Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease","enrollment":316},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT07359859","phase":"PHASE2","title":"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-20","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT06799195","phase":"PHASE2","title":"Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-06-23","conditions":"Hematological Malignancies, Graft-versus-Host Disease (GVHD)","enrollment":126},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT03357159","phase":"PHASE2","title":"Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2018-09-06","conditions":"Graft Versus Host Disease","enrollment":30},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT03699475","phase":"PHASE2, PHASE3","title":"Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS","status":"TERMINATED","sponsor":"Bellicum Pharmaceuticals","startDate":"2018-12-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT06000982","phase":"PHASE3","title":"Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-01","conditions":"GVHD","enrollment":138},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard dose PTCY","genericName":"Standard dose PTCY","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PTCY is a small molecule that targets the P2Y12 receptor. Used for Acute coronary syndrome, Myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}